Document is current
Any future updates will be listed below
-
Authors
Link, Jason M. https://orcid.org/0000-0002-6892-0431
Eng, Jennifer R. https://orcid.org/0000-0003-1499-8417
Pelz, Carl
MacPherson-Hawthorne, Kevin
Worth, Patrick J.
Sivagnanam, Shamaline https://orcid.org/0000-0001-5966-1522
Keith, Dove J. https://orcid.org/0000-0001-6104-3264
Owen, Sydney
Langer, Ellen M. https://orcid.org/0000-0003-0352-1859
Grossblatt-Wait, Alison https://orcid.org/0000-0002-2838-2595
Salgado-Garza, Gustavo
Creason, Allison L. https://orcid.org/0000-0001-5724-1276
Protzek, Sara
Egger, Julian https://orcid.org/0000-0001-8418-0069
Holly, Hannah https://orcid.org/0000-0003-2055-5372
Heskett, Michael B.
Chin, Koei https://orcid.org/0000-0001-8061-7462
Kirchberger, Nell https://orcid.org/0009-0003-7024-705X
Betre, Konjit
Bucher, Elmar
Kilburn, David
Hu, Zhi
Munks, Michael W.
English, Isabel A. https://orcid.org/0000-0002-0566-9585
Tsuda, Motoyuki
Goecks, Jeremy https://orcid.org/0000-0002-4583-5226
Demir, Emek
Adey, Andrew C. https://orcid.org/0000-0001-7648-8717
Kardosh, Adel
Lopez, Charles D.
Sheppard, Brett C.
Guimaraes, Alex
Brinkerhoff, Brian
Morgan, Terry K.
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Coussens, Lisa M. https://orcid.org/0000-0003-2389-1865
Brody, Jonathan R.
Sears, Rosalie C. https://orcid.org/0000-0003-1558-2413
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA209988)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA186241)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA196228)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA278923)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA263996)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA253472)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA217842)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA212600)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224012)
U.S. Department of Defense (PA210068)
U.S. Department of Defense (PA210068)
U.S. Department of Defense (PA210068)
American Association for Cancer Research (15-90-25-BROD)
- License Information
-
More Information
Article History
Received: 17 January 2023
Accepted: 15 November 2024
First Online: 9 January 2025
Competing interests
: Disclosures relevant to PDAC are as follows. R.C.S. declares Scientific Advisory Board (SAB)/consultancy for Rappta Therapeutics, PanCAN, PRECEDE, MOHCCN & PanCuRx Canada and Precision Panc CRUK; sponsored research for Cardiff Oncology, AstraZeneca. G.B.M. declares SAB/consultancy for Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Roche, Signalchem Lifesciences, Tarveda, Turbine and Zentalis Pharmaceuticals; Stock/options/financial for AstraZeneca, Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda and Turbine; licensed technology HRD assay to Myriad Genetics and Digital Spatial Profiler patents with Nanostring. L.M.C. declares consulting services for Cell Signaling Technologies, AbbVie, the Susan G Komen Foundation and Shasqi, received reagents and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZelBio, Hibercell and Acerta Pharma, and participates in advisory boards for Pharmacyclics, Syndax, Carisma, Verseau, CytomX, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, Zymeworks, Genenta Sciences, Pio Therapeutics, PDX Pharmaceuticals, NextCure, the AstraZeneca Partner of Choice Network, the Lustgarten Foundation and the NIH–NCI-Frederick National Laboratory Advisory Committee. J.R.B. declares SAB for Perthera, Advisory for IDEAYA and is an editor for Springer and Taylor & Francis publishing. The other authors declare no competing interests.
